Compare ADMA Biologics Inc (ADMA) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Financial Select Sector SPDR Fund — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Financial Select Sector SPDR Fund trades at $57.76. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | XLF | |
|---|---|---|
Market Cap | $2.18B | — |
Sector | Health | — |
52-Week High | $20.38 | $58.01 |
52-Week Low | $7.60 | $47.80 |
Enterprise Value | $2.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
XLF trades at $57.60, down 0.35% on the day, with a bullish technical signal driven by moving averages and strong momentum indicators. The ETF recently touched an all-time high, supported by robust inflows into financial sector ETFs and strong Q2 earnings from major banks. A dividend of $0.19 is scheduled for June 2026, adding income appeal.
Outlook remains positive given sector strength and institutional interest, though overbought RSI levels suggest near-term consolidation risks. Key opportunities include diversification benefits and yield; risks involve interest rate sensitivity and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
